Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 6, 2007, Pages 547-553

  Young, Guy ^a,b   Yonekawa, Karyn E ^a   Nakagawa, Peggy A ^a   Blain, Rachelle C ^a   Lovejoy, Amy E ^a   Nugent, Diane J ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Anticoagulation; Bleeding; Recombinant activated factor VII; Thromboelastography

Indexed keywords

ARGATROBAN; ENOXAPARIN; FONDAPARINUX; HEMOSTATIC AGENT; HEPARIN; HIRULOG; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; THROMBOPLASTIN TIME;

ANTICOAGULANTS; FACTOR VIIA; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY;

EID: 34548361909     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328201c9a9     Document Type: Article

References (23)

1. Hirsh J. Current anticoagulant therapy - unmet clinical needs. Thromb Res 2003; 15 (Suppl 1):S1-S8.
2. Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 2004; 38:99-109.
3. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2:899-909.
4. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93:1027-1035.
5. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137:884-888.
6. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14:469-477.
7. Erhardtsen E, Nony P, Dechavanne M, Efrench P, Boissel JP, Hender U. The effect of recombinant human VIIa (Novoseven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9:741-748.
8. Bijsterveld NR, Moons AH, Beokholdt SM, van Aken BE, Fennema H, Peters RJ, et al. Ability of recombinant factor VIIa to reverse the effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106:2550-2554.
9. Wolzt M, Levi M, Sarich TC, Bostrom SL, Eriksson UG, Eriksson-Lepkowska M, et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost 2004; 91:1090-1096.
10. Chan S, Kong M, Minning DM, Hedner U, Marder VJ. Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin. J Thromb Hemost 2002; 1:760-765.
11. Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis 2001; 12:327-337.
12. Shore-Lesserson L. Evidence based coagulation monitors: heparin monitoring, thromboelastography, and platelet function. Semin Cardiothorac Vasc Anesth 2005; 9:41-52.
13. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995; 108:258S-275S.
14. Lovenox prescribing information. www.lovenox.com. [Accessed 4 April 2007]
15. Arixtra prescribing information. www.arixtra.com. [Accessed 4 April 2007]
16. Argatroban prescribing information. www.argatroban.com. [Accessed 4 April 2007]
17. Angiomax prescribing information. www.angiomax.com. [Accessed 4 April 2007]
18. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11:100-106.
19. Young G, Yonekawa KE, Blain RC, Nakagawa PA, Lovejoy AE, Nugent DJ. Differential effects of direct thrombin inhibitors and antithromb-independent anticoagulants on the dynamics of clot formation. Blood Coagul Fibrinolysis 2007; 18:97-103.
20. Kessler CM. Current and future challenges of antithrombotic agents and anticoagulants: strategies for reversal of hemorrhagic complications. Semin Hematol 2004; 41 (Suppl 1):44-50.
21. Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Semin Hematol 2002; 41 (Suppl 1):65-69.
22. Malherbe S, Tsui BCH, Stobart K, Koller J. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 2004; 100:443-445.
23. Elg M, Carlsson S, Gustafson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001; 101:145-157.